EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Identification of peripheral biomarkers through metabolomic analysis in patients with bipolar disorder treated with mood stabilizers: an exploratory study

Cristina Piras, Claudia Pisanu, Martina Spada, Anna Meloni, Donatella Congiu, Vanessa Palmas, Giovanni Severino, Raffaella Ardau, Caterina Chillotti, Martina Contu, Pasquale Paribello, Marco Pinna und 7 weitere

International Journal of Neuropsychopharmacology · 01.10.2025 · 28 (10)

DOI: 10.1093/ijnp/pyaf071 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Neuropsychopharmacology, online erschienen am 24.09.2025. Verfasst von Cristina Piras und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy. Hauptthemen laut MEDLINE: Bipolar Disorder, Antimanic Agents, Metabolome. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Convenzione tra la Fondazione di Sardegna e gli Atenei Sardi, Fondazione di Sardegna.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Bipolar disorder (BD) is mainly treated with mood stabilizers, among which lithium represents the gold standard. Despite its high clinical efficacy, the molecular players involved in lithium response and nonresponse remain partly unclear. Therefore, the identification of peripheral biomarkers would significantly improve the management of pharmacological interventions in BD. Objective and Design In this study, we sought to investigate the blood metabolome in patients with BD to identify biosignatures of treatment with different mood stabilizers as well as possible biomarkers of response to lithium. Setting and Participants The blood metabolome was measured in a sample of 89 patients with BD either under prophylactic lithium treatment (n = 47), and characterized as responders or nonresponders, or with other mood stabilizers (MS, n = 42). For each patient the plasma metabolome was measured with hydrogen nuclear magnetic resonance (1H-NMR) and gas chromatography–mass spectrometry (GC-MS). Data were investigated with multivariate analyses accounting for covariates. Results Patients exposed to lithium or to other MS showed different, specific metabolic signatures, with different levels of metabolites belonging to pathways involved in glucose, pyruvate, and glutamate metabolism, which were previously suggested to be implicated in BD and to be regulated by lithium. On the other hand, we were not able to identify significant differences in the metabolomic profile between responders and nonresponders to lithium. Conclusions and Relevance The findings from this exploratory study suggest that patients treated with lithium show distinctive metabolomic biosignatures, specifically pointing to energy metabolism and mitochondria functioning, thus potentially suggesting possible biosignatures of mood-stabilizing treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bipolar DisorderAntimanic AgentsMetabolomeHumansMaleFemaleAdultBiomarkersMetabolomicsMiddle AgedGas Chromatography-Mass Spectrometry

Stichwörter der Autor:innen

biomarkersmetabolitesmood disorderspersonalized psychiatryresponse to mood stabilizers

Substanzen

BiomarkersAntimanic Agents

Autor:innen und Institutionen

  • Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy.
  • Section of Neuroscience and Clinical Pharmacology, Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy.
  • Microbiology and Virology Unit, Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy.
  • Unit of Clinical Pharmacology, University Hospital Agency of Cagliari, Cagliari, Italy.
  • Section of Psychiatry, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
  • Unit of Clinical Psychiatry, University Hospital Agency of Cagliari, Cagliari, Italy.

ORCID-Profile: Alessio Squassina

Förderung

  • Convenzione tra la Fondazione di Sardegna e gli Atenei Sardi
  • Fondazione di Sardegna

Zitieren

APA

Piras, C., Pisanu, C., Spada, M., Meloni, A., Congiu, D., Palmas, V., Severino, G., Ardau, R., Chillotti, C., Contu, M., Paribello, P., Pinna, M., Suprani, F., Del Zompo, M., Carpiniello, B., Manzin, A., Manchia, M., Atzori, L., & Squassina, A. (2025). Identification of peripheral biomarkers through metabolomic analysis in patients with bipolar disorder treated with mood stabilizers: an exploratory study. International Journal of Neuropsychopharmacology, 28(10). https://doi.org/10.1093/ijnp/pyaf071

Vancouver

Piras C, Pisanu C, Spada M, Meloni A, Congiu D, Palmas V, et al. Identification of peripheral biomarkers through metabolomic analysis in patients with bipolar disorder treated with mood stabilizers: an exploratory study. International Journal of Neuropsychopharmacology. 2025;28(10). doi:10.1093/ijnp/pyaf071

BibTeX
@article{Piras2025,
  author = {Piras, Cristina and Pisanu, Claudia and Spada, Martina and Meloni, Anna and Congiu, Donatella and Palmas, Vanessa and Severino, Giovanni and Ardau, Raffaella and Chillotti, Caterina and Contu, Martina and Paribello, Pasquale and Pinna, Marco and Suprani, Federico and Del Zompo, Maria and Carpiniello, Bernardo and Manzin, Aldo and Manchia, Mirko and Atzori, Luigi and Squassina, Alessio},
  title = {Identification of peripheral biomarkers through metabolomic analysis in patients with bipolar disorder treated with mood stabilizers: an exploratory study},
  journal = {International Journal of Neuropsychopharmacology},
  year = {2025},
  volume = {28},
  number = {10},
  doi = {10.1093/ijnp/pyaf071}
}
Kostenlos starten →